Afficher la couverture 'Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review | Branchoux, Sébastien' en grand format
/5

0 avis

Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review

Archive ouverte

Branchoux, Sébastien | Bellera, Carine | Italiano, A. | Rustand, Denis | Gaudin, A. F. | Rondeau, Virginie

Edité par CCSD ; Elsevier -

International audience. BACKGROUND: Surrogate endpoints (SEs) for overall survival (OS) are specific to therapeutic class. The objective of this review was to document all alternative endpoints studied for their association with OS in Immune-Checkpoint Inhibitors (ICI)-treated patients. METHODS: We searched PubMed and Embase for publications reporting the association between a clinical endpoint and OS in ICI-treated populations from 01/01/2003 to 03/31/2018. RESULTS: Out of 6,335 references identified, 24 were selected. Only 3 studies assessed surrogacy at both the patient and trial levels. The main traditional alternative endpoints included progression-free survival (N=10) and objective response rate (N=8). New alternative endpoints, such as durable response rate (N=1) and intermediate response endpoint (N=1) statistically better correlate with OS in the cancer types analysed. CONCLUSION: Based on the published evidence, there is insufficient data to support validated SE for OS. Adequate surrogacy assessment of promising composite endpoints which consider a duration component is encouraged.

Suggestions

Du même auteur

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial

Archive ouverte | Branchoux, S. | CCSD

International audience. BACKGROUND: Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigated TNT-D as a surrogate endp...

Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. : Crit Rev Oncol Hematol

Archive ouverte | Savina, Marion | CCSD

International audience. BACKGROUND: In cancer randomized controlled trials (RCT), alternative endpoints are increasingly being used in place of overall survival (OS) to reduce sample size, duration and cost of trial...

Surrogate endpoints in advanced sarcoma trials: a meta-analysis

Archive ouverte | Savina, Marion | CCSD

International audience. Background: Alternative endpoints to overall survival (OS) are frequently used to assess treatment efficacy in randomized controlled trials (RCT). Their properties in terms of surrogate outco...

Chargement des enrichissements...